HRTSvsETF 2ETF Comparison
VS
Choose a second ETF to run a side-by-side ETF comparison with HRTS, and assess how they stack up in performance, liquidity, risk, exposure, holdings, and more, helping you select the best ETF for your investments.
Find out how industry players manage ETF portfolios. Discover our library of Model portfolios
HRTS performance and flow charts
Performance
Cumulative Flows
Historic performance and flows
Data as of 07/29/2026
| 1M | 3M | YTD | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|---|---|
| Perf. | HRTS ETF 2 | +1.64%– | +13.48%– | +5.43%– | +32.43%– | n/a– | n/a– |
| Flows | HRTS ETF 2 | -– | -$70K– | -$2M– | -$6M– | -– | -– |
Volatility and drawdown
| 3M | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|
| Volatility | HRTS ETF 2 | +17.92%– | +16.00%– | n/a– | n/a– |
| Max drawdown | HRTS ETF 2 | -4.69%– | -10.68%– | n/a– | n/a– |
| Max drawdown duration | HRTS ETF 2 | 22d– | 170d– | n/a– | n/a– |
Trading data
HRTS | ETF 2 | |
Last sale 7/30/2026 at 1:30 PM | $36.90 | – |
| Previous close 07/29/2026 | $37.25 | – |
| Consolidated volume 07/29/2026 | ||
| Average volume 30 days | ||
| Average discount or premium 30 days | ||
| Average Bid/Ask spread 30 days |
Advertisement
Main metrics
Last update 7/30/2026 at 1:30 PM
Live
Closed
HRTS | ETF 2 | |
|---|---|---|
| Last price | $36.90 | – |
| 1D performance | -0.92% | – |
| AuM | $55.50 M | – |
| E/R | 0.99% | – |
Characteristics
HRTS | ETF 2 | |
|---|---|---|
| Management strategy | Active | – |
| Provider | Tema | – |
| Benchmark | - | – |
| N° of holdings | 43 | – |
| Asset class | - | – |
| Trailing 12m distribution yield | Join | Join |
| Inception date | November 21, 2023 | – |
| ESG | No | – |
Advertisement
Exposure
Countries
HRTS
USA
76.55%
Switzerland
7.26%
Other
16.19%
ETF 2
Sectors
HRTS
Healthcare
99.57%
Other
0.43%
ETF 2
Advertisement
Diversification
HRTS
Total weight of top 15 holdings out of 15
64.29%
ETF 2
–
Top 15 holdings
Data as of June 30, 2026
HRTS
Eli Lilly & Co.
11.91%
UnitedHealth Group, Inc.
5.58%
Novo Nordisk A/S
5.25%
Merck & Co., Inc.
4.11%
Roche Holding AG
3.96%
Thermo Fisher Scientific, Inc.
3.91%
AstraZeneca PLC
3.85%
Johnson & Johnson
3.84%
Revolution Medicines, Inc.
3.64%
Cytokinetics, Inc.
3.40%
Novartis AG
3.30%
Gilead Sciences, Inc.
3.09%
Vertex Pharmaceuticals, Inc.
3.04%
Abbott Laboratories
2.71%
Danaher Corp.
2.70%
ETF 2
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
Advertisement
Latest news about HRTS
Advertisement
